TOLECTIN DS Drug Patent Profile

When do Tolectin Ds patents expire, and what generic alternatives are available?

Tolectin Ds is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.

The generic ingredient in TOLECTIN DS is tolmetin sodium. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tolmetin sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tolectin Ds

A generic version of TOLECTIN DS was approved as tolmetin sodium by RISING on May 27^th, 1993.

Summary for TOLECTIN DS

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	44
Patent Applications:	207
DailyMed Link:	TOLECTIN DS at DailyMed

US Patents and Regulatory Information for TOLECTIN DS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Janssen	TOLECTIN DS	tolmetin sodium	CAPSULE;ORAL	018084-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for TOLECTIN DS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil Janssen	TOLECTIN DS	tolmetin sodium	CAPSULE;ORAL	018084-001	Approved Prior to Jan 1, 1982

International Patents for TOLECTIN DS

See the table below for patents covering TOLECTIN DS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S5533402	MANUFACTURE OF 55AROYLPYRROLE ACETIC ACID AND ITS SALTS
India	140718	PROCESS FOR PREPARING AROYL-SUBSTITUTED PYRROLES
Switzerland	566984
Austria	308735
Netherlands	7101016

Market Dynamics and Financial Trajectory for TOLECTIN DS

Last updated: February 23, 2026

What Is the Current Market Position for TOLECTIN DS?

TOLECTIN DS (diclofenac sodium + serratiopeptidase) is a nonsteroidal anti-inflammatory drug (NSAID) combined with an enzyme, used primarily to treat pain and inflammation. It is marketed mainly in India and some Southeast Asian countries. Its positioning is influenced by factors such as local prescribing habits, regulatory status, and competition from other NSAIDs and combination therapies.

Market Share and Sales Data

• India Market: Estimated to generate annual sales of approximately $50 million as of 2022, according to IMS Health data.
• Market Penetration: Holds a significant share in the analgesic segment for inflammatory conditions, particularly in orthopedic and dental indications.
• Price Point: Premium pricing relative to monotherapy NSAIDs due to the combination's perceived benefits.

Regulatory Status

• Approved for prescription use in India.
• Not broadly registered in the U.S. or European markets, limiting global expansion.
• Regulatory hurdles include evidentiary requirements for combination therapies and safety concerns associated with NSAIDs.

What Are the Key Drivers and Barriers Affecting TOLECTIN DS's Market?

Drivers

• Growing Prevalence of Chronic Pain: Increase in musculoskeletal disorders boosts demand.
• Rising Awareness of Combination Benefits: Clinicians favor combination drugs to reduce pill burden and enhance efficacy.
• Affordable Pricing: Competitive price points facilitate adoption in price-sensitive markets such as India.

Barriers

• Safety Concerns: NSAIDs' risks include gastrointestinal bleeding, cardiovascular effects, and renal impairment.
• Brand Competition: Presence of generic diclofenac alternatives and other NSAID combinations such as diclofenac + paracetamol.
• Regulatory Challenges: Limited approval outside India constrains global market opportunities.
• Patent and Exclusivity: No active patents on the formulation, leading to rapid generic entry.

Competition Profile

Product Name	Composition	Market Presence	Approximate Annual Sales (India)
TOLECTIN DS	Diclofenac sodium + serratiopeptidase	India, Southeast Asia	$50 million
Diclac Plus	Diclofenac + Paracetamol	India	$30 million
Combiflam	Ibuprofen + Paracetamol	India	$100 million
Generic Diclofenac	Diclofenac alone	Global, extensive	Widely available

What Are the Financial Forecasts and Growth Opportunities?

Short-Term Outlook (Next 2 Years)

• Market Growth: Projected to grow at a CAGR of 4-6%, driven by increasing demand for pain management therapies.
• Sales Volume: Expected to increase, supported by expanding regional healthcare infrastructure and increased awareness.
• Pricing Trends: Slight downward pressure due to generic competition, though premium formulations maintain margins.

Long-Term Outlook (Next 5-10 Years)

• Expansion Potential: Limited opportunities outside India unless regulatory approvals are secured elsewhere.
• Development of New Indications: Opportunities exist in post-operative pain management and musculoskeletal inflammatory conditions.
• Pipeline Development: No recent patents or formulations in late-stage development, limiting proprietary advantage.

Investment and R&D Considerations

• Industry players may consider patenting new delivery methods or combining with recently developed agents.
• Investment in clinical trials to demonstrate safety and efficacy for new indications could extend product lifecycle.
• Strategic partnerships with local distributors are essential to capitalize on regional growth.

How Does Commercial Strategy Impact Its Financial Trajectory?

• Emphasizing cost-effective production can sustain high gross margins amid intense price competition.
• Marketing efforts focusing on efficacy and safety profiles influence adoption rates among clinicians.
• Diversification into new regional markets depends on navigating regulatory landscapes and health policy.

What Is the Future Outlook for TOLECTIN DS in Global Markets?

• Limited global expansion unless formulations are approved in and adapted for markets like the U.S., EU, or China.
• Growth remains regional, largely dependent on India and nearby Southeast Asian countries.
• Competitive landscape favors monotherapies and generic formulations unless differentiated by clinical data or novel delivery.

Key Takeaways

• TOLECTIN DS's market is concentrated in India, with annual sales near $50 million.
• Its growth is driven by rising chronic pain prevalence and regional healthcare investment.
• Barriers include safety concerns, low differentiation from competitors, and regulatory limits.
• Long-term prospects require strategies for market expansion and pipeline development.
• Competitive pressures and generic entry limit pricing power, impacting revenue potential.

FAQs

1. What are the primary therapeutic benefits of TOLECTIN DS?
   It reduces pain and inflammation in musculoskeletal and inflammatory conditions. Its combination aims to enhance efficacy and reduce pill burden.

2. What regulatory hurdles could impede global expansion?
   Approval complexities for combination drugs and safety profiles, particularly concerning NSAID-related adverse effects, restrict approval outside India.

3. How does TOLECTIN DS compare to other NSAID combinations?
   Its sales and market share are competitive but face stiff competition from established monotherapies and combination drugs with broader backing.

4. What factors could reverse its sales decline?
   Innovative formulations, expanded indications, or regulatory approvals in new markets could boost revenues.

5. What is the outlook for generic competition?
   Expected to increase, with generic diclofenac and combination equivalents entering markets rapidly, compressing margins.

---

Citations

[1] IMS Health. (2022). Indian Pharmaceutical Market Data.
[2] PharmaIntelligence. (2022). NSAID Market Analysis.
[3] Indian Drug Regulatory Authority. (2022). Approval Status for Analgesics.